Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Psychosomatics ; 58(3): 217-227, 2017.
Article in English | MEDLINE | ID: mdl-28410777

ABSTRACT

BACKGROUND: Bariatric surgery is an effective means of weight reduction in severely obese patients and correlates with improvements in quality of life, mental health outcomes, and neurocognition, especially in those with high psychosocial burden. OBJECTIVE: The primary purpose of this systematic review was to evaluate the impact of bariatric surgery on long-term neurocognitive functioning and neuropsychological outcomes. METHODS: OVID Medline and PsychInfo databases from January 1990 to August 2015 were searched with key terms and phrases: "bariatric surgery" and "cognition." The inclusion criteria for the studies included the following: n ≥ 10, minimum postoperative follow-up of 12 months, and use of formal neurocognitive assessment tools presurgery and postsurgery. RESULTS: Of 422 identified abstracts, a total of 10 studies met inclusion criteria and sample sizes ranged from 10-156. Postsurgical follow-up time ranged from 12-36 months. All 10 studies documented significant improvements of statistical significance (p < 0.05) in at least 1 neurocognitive domain following bariatric surgery; 9 studies showed improvements in memory, 4 studies showed improvement in executive function, and 2 studies showed improvements in language, and 1 study showed no improvement in any neurocognitive domain. CONCLUSION: Mental health care providers should consider the effect of neurocognitive performance on presurgery psychiatric assessments for bariatric surgery and implications for psychosocial functioning postsurgery. The aforementioned effect that bariatric surgical intervention has on neurocognition underscores the complex interrelationship between metabolism and brain function. Future research should validate the use of neurocognitive screening tools presurgery and evaluate the impact of neurocognitive changes on neurocognitive, bariatric, and functional outcomes.


Subject(s)
Bariatric Surgery , Cognition , Humans , Obesity, Morbid/psychology , Obesity, Morbid/surgery
2.
PLoS One ; 12(4): e0175803, 2017.
Article in English | MEDLINE | ID: mdl-28414766

ABSTRACT

The purpose of this study was to investigate the relationship between cognitive insight and cerebral metabolism in patients suffering from psychosis. The Beck Cognitive Insight Scale (BCIS) was administered to 63 patients with psychosis undergoing Positron Emission Tomography investigation. The sample was divided into two groups considering the BCIS score. Data were analyzed using Statistical Parametric Mapping. RESULTS: patients with low insight, compared to those with high insight, showed decreased metabolism in the right fusiform gyrus, left precuneus, superior temporal gyrus and insula bilaterally, as well as increased metabolism in the left orbito-frontal gyrus (all p<0.005). Our results suggest that reduced posterior (occipito-temporo-insulo-parietal) and increased anterior (orbitofrontal) cerebral metabolism may sustain low cognitive insight in psychosis.


Subject(s)
Brain/diagnostic imaging , Cognition/physiology , Psychotic Disorders/diagnostic imaging , Adolescent , Adult , Aged , Awareness/physiology , Bipolar Disorder/diagnostic imaging , Bipolar Disorder/metabolism , Bipolar Disorder/psychology , Brain/metabolism , Brain Mapping , Female , Fluorodeoxyglucose F18 , Humans , Male , Middle Aged , Positron-Emission Tomography , Psychotic Disorders/metabolism , Psychotic Disorders/psychology , Radiopharmaceuticals , Schizophrenia/diagnostic imaging , Schizophrenia/metabolism , Schizophrenic Psychology , Young Adult
3.
J Clin Pharm Ther ; 42(1): 119-121, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27800629

ABSTRACT

WHAT IS KNOWN AND OBJECTIVE: Polymorphisms in cytochrome P450 2D6 and 2C19 can lead to interindividual differences in drug plasma concentrations, affecting clomipramine efficacy. Pharmacokinetic and pharmacogenetic analyses may improve drug therapy. CASE SUMMARY: We report the case of a depressed woman requiring higher doses than standard of clomipramine. Identification of low plasma drug levels led to extensive pharmacogenetic analyses of all genes and major functional polymorphisms reported to affect clomipramine metabolism. WHAT IS NEW AND CONCLUSION: Therapeutic drug monitoring and pharmacogenetic analyses may be useful in the investigation and optimization of clomipramine in standard-dose non-responders.


Subject(s)
Antidepressive Agents, Tricyclic/administration & dosage , Clomipramine/administration & dosage , Depressive Disorder, Major/drug therapy , Depressive Disorder, Major/genetics , Drug Monitoring/methods , Female , Humans , Middle Aged , Pharmacogenetics/methods , Polymorphism, Genetic/genetics
4.
Psychiatry Res ; 230(2): 172-80, 2015 Dec 15.
Article in English | MEDLINE | ID: mdl-26350702

ABSTRACT

Neurocognitive and social cognition deficits have been largely reported in Schizophrenia (SKZ) but their association with psychopathology remains uncertain. Our purpose was to explore the relationship between symptom dimensions and neuropsychological performances. We enrolled 35 stabilized schizophrenic outpatients of the Department of Psychiatry of Policlinico Hospital, University of Milan, who completed psychiatric Rating Scales, the Brief Assessment of Cognition in Schizophrenia (BACS) and the Executive and Social Cognition Battery (ESCB). Disorganized dimension seems to have the most significant impact on cognition, being associated with performance in several BACS subtests (verbal memory, working memory, motor speed, symbol coding, Tower of London) and ESCB tasks (MET and Hotel task number of tasks attempted, number of broken MET rules, sum of deviations in Hotel Task). Positive dimension correlated with performance in verbal fluency, negative dimension with IOWA Test results, cognitive dimension with MET number of inefficiencies and Eyes test score. Impulsive-aggressive and depressive dimensions weakly correlated only with Faux Pas test. Our study supports the existence of a specific disorganized dimension in SKZ, separated from cognitive dimension evaluated through clinical instruments (e.g. PANSS), but capable of influencing cognitive abilities. Furthermore, it strengthens the validity of ecological tasks in evaluating cognition in SKZ.


Subject(s)
Cognition Disorders/diagnosis , Schizophrenia, Disorganized/physiopathology , Schizophrenia, Disorganized/psychology , Schizophrenic Psychology , Social Behavior , Adult , Cognition , Female , Humans , Male , Memory, Short-Term , Middle Aged , Neuropsychological Tests , Young Adult
5.
J Affect Disord ; 182: 70-5, 2015 Aug 15.
Article in English | MEDLINE | ID: mdl-25978716

ABSTRACT

BACKGROUND: A number of data show the negative role of duration of untreated illness (DUI) on outcome in mood disorders, but no investigation has been carried out about the impact of this variable in bipolar disorder (BD) with psychotic symptoms. Clinical experience shows that many bipolar patients with psychotic symptoms receive other diagnoses and often are chronically treated with first generation antipsychotics, with the effect to reduce duration of untreated psychosis/untreated episode with psychotic symptoms (DUP), but not DUI. Purpose of the study was to define the rate of misdiagnosis and the impact of DUP/DUI on outcome of bipolar patients with psychotic symptoms. METHOD: Clinical information (DUP, DUI, first received diagnosis) about bipolar outpatients with psychotic symptoms (N=240) were extrapolated through a retrospective review of the clinical charts, Lombardy database and, if necessary, through clinical interviews with patients and their relatives. Outcome measures included psychiatric and substance abuse comorbidity, occupational status, Global Assessment of Functioning (GAF), number of hospitalizations and of suicidal attempts, number of depressive/manic recurrences. Patients were divided in two groups according to the DUP (1 year) and DUI (8 years) median, and the groups were compared through analyses of variance (ANOVAs) for continuous variables or χ(2) tests for dichotomous ones. Multivariate analysis of variance (MANOVA) with duration of illness as covariate was then performed to eliminate the effect of this variable. Finally, binary logistic regressions were performed considering age at onset, DUI, DUP as independent variables and outcome variables as dependent ones (presence of hospitalizations/suicidal attempts, GAF scores<50, occupational status). RESULTS: Most of patients (61.5%) received a first diagnosis different from BD with the most frequent DSM-diagnosis being delusional disorder (17.9%). Patients with longer DUP were not different in outcome measures with respect to patients with shorter DUP. Patients with a DUI >8 years presented higher number of hospitalizations (F=6.04, p=0.015), higher number of manic recurrences (F=5.25, p=0.023), higher number of depressive recurrences (F=7.13, p=0.008) and lower GAF scores (F=17.74, p<0.001). Statistical significance persisted for number of hospitalizations (p<0.001) and GAF scores (p=0.003) after MANOVA. Finally binary logistic regression showed that a longer DUI was predictive of GAF scores<50 (F=17.74, p<0.001). DISCUSSION: More than half of bipolar patients with psychotic symptoms receive a different diagnosis at first contact with psychiatric services. DUI (but not DUP) is a predictor of outcome in bipolar patients with psychotic symptoms. This indicates that an early diagnosis and proper treatment with a mood stabilizer (or an atypical antipsychotic with mood stabilizing effects) may improve long-term outcome of these patients. In the light of the naturalistic design of the present paper, these results have to be considered as preliminary and have to be confirmed by prospective controlled studies.


Subject(s)
Antipsychotic Agents/therapeutic use , Bipolar Disorder/complications , Bipolar Disorder/drug therapy , Diagnostic Errors/statistics & numerical data , Psychotic Disorders/complications , Psychotic Disorders/drug therapy , Analysis of Variance , Bipolar Disorder/psychology , Comorbidity , Diagnostic Errors/psychology , Female , Hospitalization , Humans , Male , Middle Aged , Prospective Studies , Psychotic Disorders/psychology , Retrospective Studies , Suicide, Attempted , Time Factors , Treatment Outcome
6.
Bipolar Disord ; 16(7): 769-72, 2014 Nov.
Article in English | MEDLINE | ID: mdl-24499389

ABSTRACT

OBJECTIVE: Recent data have shown that genetic variability in the progranulin (GRN) gene may contribute to the susceptibility to developing bipolar disorder (BD). However, in regard to patients with BD, no information is available on the role of genetic variability and plasma progranulin levels in different types of this disorder. METHODS: In this study, we performed an association analysis of GRN in an Italian population consisting of 134 patients with BD and 232 controls to evaluate progranulin plasma levels. RESULTS: The presence of the polymorphic variant of the rs5848 single nucleotide polymorphism is protective for the development of bipolar I disorder (BD-I) (odds ratio = 0.55, 95% confidence interval: 0.33-0.93; p = 0.024) but not bipolar II disorder (BD-II) (p > 0.05). In addition, plasma progranulin levels are significantly decreased in BD [mean ± standard deviation (SD) 112 ± 35 versus 183 ± 93 ng/mL in controls; p < 0.001]. CONCLUSIONS: Regarding the influence of GRN variability on BD susceptibility, the predisposing genetic background differs between BD-I and BD-II, possibly implying that pathogenic mechanisms differ between the two subtypes of BD.


Subject(s)
Bipolar Disorder/genetics , Genetic Predisposition to Disease , Intercellular Signaling Peptides and Proteins/genetics , Polymorphism, Single Nucleotide/genetics , Adult , Aged , Bipolar Disorder/blood , Bipolar Disorder/classification , Case-Control Studies , Female , Genotype , Humans , Intercellular Signaling Peptides and Proteins/blood , Italy , Male , Middle Aged , Odds Ratio , Progranulins , Young Adult
7.
Front Hum Neurosci ; 7: 661, 2013.
Article in English | MEDLINE | ID: mdl-24146642

ABSTRACT

This study aimed to determine the extent of impairment in social and non-social cognitive domains in an ecological context comparing bipolar (BD), schizophrenic (SKZ) patients and healthy controls (HC). The sample was enrolled at the Department of Psychiatry of Policlinico Hospital, University of Milan; it includes stabilized SKZ patients (n = 30), euthymic bipolar patients (n = 18) and HC (n = 18). Patients and controls completed psychiatric assessment rating scales, the Brief Assessment of Cognition in Schizophrenia (BACS) and the Executive and Social Cognition Battery (ESCB) that contains both ecological tests of executive function and social cognition, in order to better detect cognitive deficits in patients with normal results in standard executive batteries. The three groups differed significantly for gender and substance abuse, however, the differences did not influence the results. BD patients showed less impairment on cognitive performance compared to SKZ patients, even in "ecological" tests that mimic real life scenarios. In particular, BD performed better than SKZ in verbal memory (p < 0.0038) and BACS symbol coding (p < 0.0043). Regarding the ESCB tests, in the Hotel task SKZ patients completed significantly less tasks (p < 0.001), showed a greater number of errors in Multiple Errands Test (MET-HV) (p < 0.0248) and a worse performance in Theory of Mind (ToM) tests (p < 0.001 for the Eyes test and Faux pas test). Both patients' groups performed significantly worse than HC. Finally, significant differences were found between the two groups in GAF scores, being greater among BD subjects (p < 0.001). GAF was correlated with BACS and ESCB scores showing the crucial role of cognitive and ecological performances in patients' global functioning.

SELECTION OF CITATIONS
SEARCH DETAIL
...